Blog
RSS FeedPosted by Michael Wonder on 19 Sep 2025
Biocon Biologics' Yesafili (aflibercept) now publicly funded in Ontario, Canada for the advanced treatment of patients with retinal diseases
18 September 2025 - -- Biocon Biologics is pleased to announce that Yesafili (aflibercept), a biosimilar to Eylea (aflibercept) injection, ...
Posted by Michael Wonder on 10 Sep 2025
Enhanced access to generalised myasthenia gravis treatments: UCB Canada secures pCPA agreements for Zilbrysq and Rystiggo
9 September 2025 - Important milestone brings eligible Canadians living with generalised myasthenia gravis one step closer to accessing innovative ...
Posted by Michael Wonder on 10 Sep 2025
Pfizer's Prevnar 20 selected for pneumococcal public immunisation program in British Columbia
9 September 2025 - Today, Pfizer Canada announced that its 20 valent pneumococcal conjugate vaccine, Prevnar 20, has been selected for ...
Posted by Michael Wonder on 31 Aug 2025
Vabysmo (faricimab injection) now publicly funded for macular oedema secondary to retinal vein occlusion in Ontario
29 August 2025 - Roche Canada is pleased to announce today that Vabysmo (faricimab injection) is now publicly funded for ...
Posted by Michael Wonder on 16 Aug 2025
Vabysmo (faricimab injection) now publicly funded for macular oedema secondary to retinal vein occlusion and pre-filled syringe in Quebec
15 August 2025 - Vabysmo now covered across all three approved indications in the province, providing patients with a comprehensively ...
Posted by Michael Wonder on 08 Aug 2025
Alexion, AstraZeneca Rare Disease reaches an agreement with the pan-Canadian Pharmaceutical Alliance for Ultomiris for the treatment of adults with neuromyelitis optica spectrum disorder and adults with generalised myasthenia gravis
7 August 2025 - The agreement is a critical step in ensuring adult patients living with NMOSD and gMG have ...
Posted by Michael Wonder on 08 Aug 2025
Access to multiple sclerosis treatments inadequate in British Columbia
7 August 2025 - Teresa Alfeld, a filmmaker who was recently diagnosed with multiple sclerosis, is calling for the provincial ...
Posted by Michael Wonder on 27 Mar 2025
ViiV Healthcare announces reimbursement for Apretude for HIV-1 pre-exposure prophylaxis under the Non-Insured Health Benefits (NIHB) Program
25 March 2025 - ViiV Healthcare is pleased to announce that Apretude (cabotegravir tablets and extended release injectable suspension) is ...
Posted by Michael Wonder on 25 Mar 2025
Government of Canada signs bilateral agreement with Quebec for Drugs for Rare Diseases
21 March 2025 - In Canada, one in 12 people live with a rare disease, and for most people affected, the ...
Posted by Michael Wonder on 28 Feb 2025
Government of Canada signs Pharmacare agreement with Manitoba to improve affordable access to medications
27 February 2025 - Additional agreement will improve access and affordability of drugs for rare diseases. ...
Posted by Michael Wonder on 28 Jan 2025
Drugs for rare diseases – Ontario agreement
24 January 2025 - Today, the Governments of Canada and the province of Ontario signed the National Strategy for Drugs ...
Posted by Michael Wonder on 06 Dec 2024
Government of Canada signs bilateral agreement with Alberta to improve access to drugs for rare diseases
5 December 2024 - Today, the Honourable Mark Holland, Canada's Minister of Health, and the Honourable Adriana LaGrange, Alberta's Minister ...
Posted by Michael Wonder on 27 Nov 2024
Lilly Canada remains steadfast in commitment to access options for patients amidst controversial CDA-AMC recommendation for Ebglyss (lebrikizumab)
19 November 2024 - Eli Lilly Canada is disappointed and strongly disagrees with Canada's Drug Agency (CDA-AMC)'s Final Recommendation for Ebglyss ...
Posted by Michael Wonder on 04 Nov 2024
NS parents dismayed by lack of access to new RSV vaccines for infants
3 November 2024 - Officials say there is no universally available, publicly funded RSV vaccine program for newborns in Nova Scotia. ...
Posted by Michael Wonder on 20 Sep 2024
BioCryst and the pan-Canadian Pharmaceutical Alliance successfully complete negotiations for Orladeyo (berotralstat), an oral, once daily therapy for the prevention of hereditary angioedema attacks
17 September 2024 - BioCryst Pharmaceuticals today announced that it successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance for oral, ...